Jazz Pharmaceuticals shared a post on LinkedIn:
“News for U.S. media and investors: Today marks a milestone as our Phase 3 study results for HER2+ gastroesophageal adenocarcinoma (GEA), a rare and difficult-to-treat cancer, are published in The New England Journal of Medicine (NEJM Group).
The publication includes expanded safety, subgroup and sensitivity analyses that add important depth and context to the data, reflecting our continued commitment to patients with rare diseases and limited treatment options.”
Other articles about Jazz Pharmaceuticals on OncoDaily.